News | January 27, 2023
Sun Pharma launches SEZABY in the US for treatment of neonatal seizures
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection
The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022
Cell sorting technology supports researchers advancing new therapies
USFDA issued issued Form 483 with nine observations, which will be addressed within stipulated time.
It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
Connectivity and harmonisation were both key driving factors behind our decision to choose the CARA Life Sciences Platform to consolidate our processes
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
Subscribe To Our Newsletter & Stay Updated
